Geovax Labs Inc SEC Filings

GEOVAX LABS, INC. ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 291,155 shares of Common Stock, representing 9.99% of the class as set forth in this amendment. The filing states Armistice Capital exercises shared voting and dispositive power over those shares.

GeoVax Labs reported a first quarter 2026 net loss of $5.3 million, similar to the $5.4 million loss a year earlier. Revenue fell to zero from $1.6 million in first quarter 2025 after termination of its BARDA/RRPV government contract for the GEO-CM04S1 COVID-19 program.

Research and development expenses declined to $3.9 million from $5.4 million, and general and administrative costs fell to $1.4 million from $1.7 million. Cash and cash equivalents were $1.3 million as of March 31, 2026, down from $3.1 million at December 31, 2025, with stockholders’ equity at $0.5 million.

Operationally, GeoVax highlighted plans to initiate an EMA-supported Phase 3 immunobridging trial for its GEO-MVA mpox/smallpox vaccine in the second half of 2026 and continued positioning of its Gedeptin® immuno-oncology platform, including an exclusive license from Emory University covering combinations with immune checkpoint inhibitors.

GeoVax Labs reported a first quarter 2026 net loss of $5.3 million, similar to the $5.4 million loss a year earlier. Revenue fell to zero from $1.6 million in first quarter 2025 after termination of its BARDA/RRPV government contract for the GEO-CM04S1 COVID-19 program.

Research and development expenses declined to $3.9 million from $5.4 million, and general and administrative costs fell to $1.4 million from $1.7 million. Cash and cash equivalents were $1.3 million as of March 31, 2026, down from $3.1 million at December 31, 2025, with stockholders’ equity at $0.5 million.

Operationally, GeoVax highlighted plans to initiate an EMA-supported Phase 3 immunobridging trial for its GEO-MVA mpox/smallpox vaccine in the second half of 2026 and continued positioning of its Gedeptin® immuno-oncology platform, including an exclusive license from Emory University covering combinations with immune checkpoint inhibitors.

GeoVax Labs reported a first-quarter 2026 net loss of $5.26 million, similar to the prior year, but with a much weaker balance sheet. Revenue from government contracts fell to zero after termination of a BARDA contract that had generated $1.64 million in Q1 2025.

Research and development spending was $3.90 million and general and administrative expenses were $1.37 million, both lower than a year earlier as certain program and investor-relations costs declined. Cash and cash equivalents dropped to $1.27 million as of March 31 2026, with working capital of $0.14 million.

The company financed operations through equity offerings, an at-the-market program, and warrant exercises raising roughly $1.72 million in the quarter, plus additional inducement-related warrant exercises in May. Management states existing cash is expected to fund operations only into June 2026 and discloses substantial doubt about GeoVax’s ability to continue as a going concern.

GeoVax Labs reported a first-quarter 2026 net loss of $5.26 million, similar to the prior year, but with a much weaker balance sheet. Revenue from government contracts fell to zero after termination of a BARDA contract that had generated $1.64 million in Q1 2025.

Research and development spending was $3.90 million and general and administrative expenses were $1.37 million, both lower than a year earlier as certain program and investor-relations costs declined. Cash and cash equivalents dropped to $1.27 million as of March 31 2026, with working capital of $0.14 million.

The company financed operations through equity offerings, an at-the-market program, and warrant exercises raising roughly $1.72 million in the quarter, plus additional inducement-related warrant exercises in May. Management states existing cash is expected to fund operations only into June 2026 and discloses substantial doubt about GeoVax’s ability to continue as a going concern.

GeoVax Labs, Inc. reports that, as of March 31, 2026, each of the reporting persons — Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC — may be deemed to beneficially own 233,337 shares of common stock, representing 9.99% of the class. The 233,337 shares combine 121,200 shares held directly by Intracoastal and 112,137 shares issuable upon exercise of an Intracoastal warrant. The filing states there are 2,223,577 shares outstanding as of February 17, 2026 used for this calculation and describes multiple additional warrants with blocker provisions that limit exercise and additional ownership; without those blockers the reporting persons could be deemed to beneficially own 1,226,217 shares.

GeoVax Labs, Inc. reports that, as of March 31, 2026, each of the reporting persons — Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC — may be deemed to beneficially own 233,337 shares of common stock, representing 9.99% of the class. The 233,337 shares combine 121,200 shares held directly by Intracoastal and 112,137 shares issuable upon exercise of an Intracoastal warrant. The filing states there are 2,223,577 shares outstanding as of February 17, 2026 used for this calculation and describes multiple additional warrants with blocker provisions that limit exercise and additional ownership; without those blockers the reporting persons could be deemed to beneficially own 1,226,217 shares.

GeoVax Labs, Inc. entered into a warrant inducement transaction with institutional investors, who agreed to immediately exercise existing warrants to purchase 501,144 shares of common stock for gross cash proceeds of approximately $595,000, before fees and expenses.

In return, the investors will receive new unregistered warrants to purchase up to 1,002,288 shares of common stock at an exercise price of $1.65 per share. The new warrants will become exercisable after shareholder approval of the underlying shares and will expire five years after that approval date. GeoVax engaged A.G.P./Alliance Global Partners as exclusive financial advisor, paying a 7.0% cash fee on gross proceeds and reimbursing up to $40,000 of legal expenses.

GeoVax Labs, Inc. entered into a warrant inducement transaction with institutional investors, who agreed to immediately exercise existing warrants to purchase 501,144 shares of common stock for gross cash proceeds of approximately $595,000, before fees and expenses.

In return, the investors will receive new unregistered warrants to purchase up to 1,002,288 shares of common stock at an exercise price of $1.65 per share. The new warrants will become exercisable after shareholder approval of the underlying shares and will expire five years after that approval date. GeoVax engaged A.G.P./Alliance Global Partners as exclusive financial advisor, paying a 7.0% cash fee on gross proceeds and reimbursing up to $40,000 of legal expenses.

GeoVax Labs, Inc. is calling a June 17, 2026 annual stockholder meeting in Atlanta to elect seven directors, approve two key warrant-exercise share issuances, ratify its independent auditor, and hold advisory votes on executive pay and the future frequency of say‑on‑pay votes.

The proxy details board structure, director and executive biographies, compensation, equity plans, and large 2025–2026 capital raises using common stock, pre‑funded warrants, and common warrants, including new February and March 2026 warrant structures that require stockholder approval before full exercise.

GeoVax Labs, Inc. is calling a June 17, 2026 annual stockholder meeting in Atlanta to elect seven directors, approve two key warrant-exercise share issuances, ratify its independent auditor, and hold advisory votes on executive pay and the future frequency of say‑on‑pay votes.

The proxy details board structure, director and executive biographies, compensation, equity plans, and large 2025–2026 capital raises using common stock, pre‑funded warrants, and common warrants, including new February and March 2026 warrant structures that require stockholder approval before full exercise.

GeoVax Labs, Inc. reported 2025 results showing a smaller annual loss alongside lower research spending as it advanced its GEO-MVA mpox/smallpox vaccine toward a pivotal Phase 3 trial planned for the second half of 2026.

For the year ended December 31, 2025, net loss was $21.5 million, or $22.40 per share, improving from a net loss of $25.0 million, or $120.46 per share, in 2024. Revenue from a government contract related to the BARDA/RRPV Project NextGen award was $2.5 million, down from $4.0 million after BARDA terminated the contract for convenience.

Research and development expenses fell to $18.1 million from $23.7 million, mainly due to discontinued BARDA-related costs and lower GEO-CM04S1 and Gedeptin spending. General and administrative expenses increased to $6.0 million from $5.4 million, driven by higher personnel, investor relations, patent, and stock-based compensation costs. GeoVax ended 2025 with $3.1 million in cash and equivalents and total assets of $6.3 million, compared with $5.5 million in cash and $8.2 million in total assets a year earlier.

GeoVax Labs, Inc. reported 2025 results showing a smaller annual loss alongside lower research spending as it advanced its GEO-MVA mpox/smallpox vaccine toward a pivotal Phase 3 trial planned for the second half of 2026.

For the year ended December 31, 2025, net loss was $21.5 million, or $22.40 per share, improving from a net loss of $25.0 million, or $120.46 per share, in 2024. Revenue from a government contract related to the BARDA/RRPV Project NextGen award was $2.5 million, down from $4.0 million after BARDA terminated the contract for convenience.

Research and development expenses fell to $18.1 million from $23.7 million, mainly due to discontinued BARDA-related costs and lower GEO-CM04S1 and Gedeptin spending. General and administrative expenses increased to $6.0 million from $5.4 million, driven by higher personnel, investor relations, patent, and stock-based compensation costs. GeoVax ended 2025 with $3.1 million in cash and equivalents and total assets of $6.3 million, compared with $5.5 million in cash and $8.2 million in total assets a year earlier.

GeoVax Labs, Inc. is a clinical-stage biotech developing vaccines and immunotherapies for infectious diseases and solid tumors, built mainly on its Modified Vaccinia Ankara (MVA) platform and the Gedeptin gene-directed cancer therapy.

The company’s lead near-term program is GEO-MVA, an mpox/smallpox vaccine being advanced on an expedited European regulatory pathway, with a pivotal Phase 3 immuno-bridging trial planned for the second half of 2026. Oncology candidate Gedeptin completed a multicenter Phase 1/2 head and neck cancer trial and is being prepared for a Phase 2 study in combination with an immune checkpoint inhibitor, targeted to start in the first half of 2027.

COVID-19 vaccine GEO-CM04S1 is in multiple Phase 2 trials in immunocompromised patients and as a booster; an interim review in a CLL study supported continued enrollment in the investigational arm after the mRNA control failed its primary immune endpoint. A BARDA-backed Phase 2b effort under Project NextGen was later terminated for convenience, after GeoVax had met all milestones.

The company reported a $21.5 million net loss for 2025 and research and development expenses of $18.1 million, and its auditors issued a going concern opinion. GeoVax states its existing cash is expected to fund operations into the middle of the second quarter of 2026, and it highlights a need for substantial additional capital to continue advancing its pipeline.

GeoVax Labs, Inc. is a clinical-stage biotech developing vaccines and immunotherapies for infectious diseases and solid tumors, built mainly on its Modified Vaccinia Ankara (MVA) platform and the Gedeptin gene-directed cancer therapy.

The company’s lead near-term program is GEO-MVA, an mpox/smallpox vaccine being advanced on an expedited European regulatory pathway, with a pivotal Phase 3 immuno-bridging trial planned for the second half of 2026. Oncology candidate Gedeptin completed a multicenter Phase 1/2 head and neck cancer trial and is being prepared for a Phase 2 study in combination with an immune checkpoint inhibitor, targeted to start in the first half of 2027.

COVID-19 vaccine GEO-CM04S1 is in multiple Phase 2 trials in immunocompromised patients and as a booster; an interim review in a CLL study supported continued enrollment in the investigational arm after the mRNA control failed its primary immune endpoint. A BARDA-backed Phase 2b effort under Project NextGen was later terminated for convenience, after GeoVax had met all milestones.

The company reported a $21.5 million net loss for 2025 and research and development expenses of $18.1 million, and its auditors issued a going concern opinion. GeoVax states its existing cash is expected to fund operations into the middle of the second quarter of 2026, and it highlights a need for substantial additional capital to continue advancing its pipeline.

GEOVAX LABS, INC. ownership update: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 2,675,610 common shares, representing 8.26% of the outstanding common stock as of 12/31/2025.

The filing states Armistice Capital exercises shared voting and shared dispositive power over those shares through its role as investment manager to Armistice Capital Master Fund Ltd., and Mr. Boyd is reported as the managing member. The Master Fund disclaims direct beneficial ownership by virtue of the Investment Management Agreement.

GEOVAX LABS, INC. ownership update: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 2,675,610 common shares, representing 8.26% of the outstanding common stock as of 12/31/2025.

The filing states Armistice Capital exercises shared voting and shared dispositive power over those shares through its role as investment manager to Armistice Capital Master Fund Ltd., and Mr. Boyd is reported as the managing member. The Master Fund disclaims direct beneficial ownership by virtue of the Investment Management Agreement.

GeoVax Labs, Inc. entered into definitive agreements for a registered direct offering of 432,902 shares of common stock or pre-funded warrants at $2.31 per share (or $2.30999 per pre-funded warrant), together with a concurrent private placement of Series A-1 and A-2 common warrants.

The company expects gross proceeds of about $1 million and net proceeds of approximately $865,000, and plans to use the cash for working capital, general corporate purposes and to advance its product candidates. The deal includes 432,902 Series A-1 and 432,902 Series A-2 warrants at a $2.31 exercise price, exercisable after stockholder approval, and a repricing of 236,000 existing warrants down to $2.31 per share.

GeoVax Labs, Inc. entered into definitive agreements for a registered direct offering of 432,902 shares of common stock or pre-funded warrants at $2.31 per share (or $2.30999 per pre-funded warrant), together with a concurrent private placement of Series A-1 and A-2 common warrants.

The company expects gross proceeds of about $1 million and net proceeds of approximately $865,000, and plans to use the cash for working capital, general corporate purposes and to advance its product candidates. The deal includes 432,902 Series A-1 and 432,902 Series A-2 warrants at a $2.31 exercise price, exercisable after stockholder approval, and a repricing of 236,000 existing warrants down to $2.31 per share.